Therapeutic effect of losecplatin combined with compound matrine in the intraperitoneal perfusion treatment of ovarian cancer with malignant ascites and its effect on TNF

Objective To evaluate the effect of losecplatin combined with compound matrine in the intraperitoneal perfusion treatment of ovarian cancer with malignant ascites and its influence on the levle of serum tumor necrosis factor alpha(TNF-) of ovarian cancer marker. Methods 60 ovarian cancer patients with malignant ascites were divided into three groups: losecplatin combined with compound matrine perfusion group(combination group), single losecplatin perfusion group(losecplatin group) and single compound matrine perfusion group(compound matrine group), 20 cases in each group.Before treatment, all the three groups were drained intraperitoneal fluid, then given the above-mentioned group of intraperitoneal perfusion therapy.The effects, side effects and serum TNF-levels of the three groups were compared. Results The patients of the three groups were successfully completed treatment, the effective rate of the combination group was 95%, which of the losecplatin group was 60%, which of the compound matrine group was 55%.The effective rate of the combination group was significantly higher than that of the single drug group(χ2=7.025, P 0.05). The serum TNF-levels of the three groups after the perfusion treatment were significantly decreased(t=15.40, 13.82, 8.90, all P<0.05), TNF-level of the combination group was significantly lower, the difference was statistically significant(F=9.719, P<0.05). Conclusion Losecplatin combined with compound matrine in the intraperitoneal perfusion is a more effective method for the treatment of ovarian cancer with malignant ascites, which is worthy of promotion. Key words: Ovarian neoplasms; Ascites; Cytokines; Lobaplatin; Compound matrine